Complement factor P is a ligand for the natural killer cell-activating receptor NKp46

Archive ouverte

Narni-Mancinelli, Emilie | Gauthier, Laurent | Baratin, Myriam | Guia, Sophie | Fenis, Aurore | Deghmane, Ala-Eddine | Rossi, Benjamin | Fourquet, Patrick | Escalière, Bertrand | Kerdiles, Yann M. | Ugolini, Sophie | Taha, Muhamed-Kheir | Vivier, Eric

Edité par CCSD ; American Association for the Advancement of Science (AAAS) -

International audience. Innate lymphoid cells (ILCs) are involved in immune responses to microbes and various stressed cells, such as tumor cells. They include group 1 [such as natural killer (NK) cells and ILC1], group 2, and group 3 ILCs. Besides their capacity to respond to cytokines, ILCs detect their targets through a series of cell surface-activating receptors recognizing microbial and nonmicrobial ligands. The nature of some of these ligands remains unclear, limiting our understanding of ILC biology. We focused on NKp46, which is highly conserved in mammals and expressed by all mature NK cells and subsets of ILC1 and ILC3. We show here that NKp46 binds to a soluble plasma glycoprotein, the complement factor P (CFP; properdin), the only known positive regulator of the alternative complement pathway. Consistent with the selective predisposition of patients lacking CFP to lethal Neisseria meningitidis (Nm) infections, NKp46 and group 1 ILCs bearing this receptor were found to be required for mice to survive Nm infection. Moreover, the beneficial effects of CFP treatment for Nm infection were dependent on NKp46 and group 1 NKp46(+)ILCs. Thus, group 1 NKp46(+)ILCs interact with the complement pathway, via NKp46, revealing a cross-talk between two partners of innate immunity in the response to an invasive bacterial infection.

Suggestions

Du même auteur

Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells

Archive ouverte | Andre, Pascale | CCSD

International audience. Checkpoint inhibitors have revolutionized cancer treatment. However, only a minority of patients respond to these immunotherapies. Here, we report that blocking the inhibitory NKG2A receptor ...

Type 1 Innate Lymphoid Cells Limit the Antitumoral Immune Response

Archive ouverte | Vienne, Margaux | CCSD

International audience. Natural killer (NK) cells are known to be able to kill established tumor cell lines, but important caveats remain regarding their roles in the detection and elimination of developing primary ...

Activating and inhibitory receptors expressed on innate lymphoid cells

Archive ouverte | Guia, Sophie | CCSD

International audience. Innate lymphoid cells (ILCs) are innate immune cells located in lymphoid and non-lymphoid tissues. They are particularly abundant at mucosal and barrier surfaces. Three major ILC subsets are ...

Chargement des enrichissements...